NCT05161208已完成4 期
Randomized, Controlled, Double-masked Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline) Nasal Spray on Objective and Subjective Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- CLDEQ-8 scores at 4 weeks
研究概览
简要总结
This study is a single center, prospective, randomized, controlled, double-masked, two-arm investigator-initiated study to investigate the efficacy of OC-01 (varenicline) nasal spray on the signs and symptoms of dry eye disease in daily soft contact lens wearers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provide signed written consent prior to study-related procedures.
- •Be ages 18 to 70
- •Is a symptomatic CL wearer with a CLDEQ-8 score of ≥12 points at baseline at the end of wear time.
- •Soft contact lens wearers with self-reported complaints of dryness and/or reduced contact lens wear time.
- •Wear soft contact lenses 2 or more days a week for more than 1 month in both eyes.
- •Currently wears daily soft lenses in both eyes, for a minimum of 2 days/week for 6 hours/day over the last month, and is willing to continue to do so during the study.
- •Have a current contact lens prescription.
- •Best corrected visual acuity of 20/25-2 or better in each eye (Can achieve acceptable lens fit as well as visual acuity (VA) correctable to logMAR +0.10 or better in each eye with their habitual contact lens type).
- •History or current use of artificial tears at least once in the last 30 days.
- •Be literate and able to complete questionnaires independently.
- •Be able and willing to use the study drug and participate in all study assessments and visits.
- •Have sufficient hand strength, in the opinion of the Investigator, to be able to independently administer the study drug.
- •Have provided written informed consent.
- •If a female is of childbearing potential, they must not plan to get pregnant during the study.
排除标准
- •Wearing soft CLs on an extended wear basis (i.e. overnight) or is a rigid gas permeable lens or hybrid lens wearer
- •Patients with dry eye complaints that the investigator deems are not related to dry eyes will be discontinued at Visit
- •Using prescription eyedrops for the treatment of dry eye disease (ex. Steroids, Lifitegrast, Cyclosporine)
- •Clinically significant ocular trauma.
- •Active or Inactive ocular Herpes simplex or Herpes Zoster infection
- •Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
- •Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
- •Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
- •Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
- •Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
- •Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
- •Have had nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas
- •Be currently treated with nasal continuous positive airway pressure
- •Have any untreated nasal infection at Visit 1
- •Have a vascularized polyp, severely deviated septum, chronic recurrent nosebleeds, or severe nasal obstruction.
- •Have current concomitant use of a nicotinic acetylcholine receptor agonist [Nicoderm®, Nicorette®, Nicotrol NS® (nicotine), Tabex®, Desmoxan® (cytisine), and Chantix® (varenicline)] within the previous 30 days of Visit 1 and during the treatment period.
- •Use of topical presecription ophthalmic medications including cyclosporine, liftegrast, steroids, non-steroidal anti-inflammatory drugs, anti-glaucoma medications within 7 days of screening or during study period.
- •Prescription and OTC ophthalmic mast cell stabilizers and antihistamines within 21 days of screening and throughout study period (systemic permitted.)
- •Have a known hypersensitivity to any of the procedural agents or study drug components
- •Have active or uncontrolled, severe at the discretion of the investigator: (a) Systemic allergy, (b) Chronic seasonal allergies at risk of being active during the study treatment period, (c) Rhinitis or sinusitis requiring treatment such as antihistamines, decongestants, oral or aerosol steroids at the Screening Visit or be expected to require treatment during the treatment period of the study
- •Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1 and during the treatment period.
- •Be a female who is pregnant, nursing, or planning a pregnancy at Visit
- •Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner.
研究组 & 干预措施
OC-01 (varenicline 0.6mg/ml) nasal spray
Experimental
Intranasal delivery of OC-01 nasal spray twice daily (BID)
干预措施: OC-01 (varenicline 0.6mg/ml) Nasal Spray (Drug)
Placebo (vehicle) nasal spray
Placebo Comparator
Intranasal delivery of placebo vehicle nasal spray twice daily (BID)
干预措施: Placebo (vehicle) nasal spray (Drug)
结局指标
主要结局
CLDEQ-8 scores at 4 weeks
时间窗: 4 weeks
Mean change in CLDEQ-8 scores from baseline to week 4
Contact lens wear time at 4 weeks
时间窗: 4 weeks
Mean change in comfortable wear time, overall wear time, and utilization of artificial tears from baseline to week 4 as measured by virtual daily log
次要结局
- Contact lens wear time at 8 weeks(8 weeks)
- CLDEQ-8 scores at 8 weeks(8 weeks)
- Automated tear breakup time(8 weeks)
- Tearscope tear breakup time(8 weeks)
- Vital staining score(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Safety and Activity Study of NS2 in Subjects With Allergic ConjunctivitisAllergic ConjunctivitisSeasonal AllergiesNCT02578914Aldeyra Therapeutics, Inc.100
已完成
4 期
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic ConjunctivitisAllergic ConjunctivitisNCT05314621Andover Research Eye Institute61
已完成
3 期
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle GlaucomaGlaucoma, Open-AngleNCT04890106Mankind Pharma Limited310
已完成
2 期
A Safety and Efficacy Study of NS2 in Patients With Anterior UveitisNon-infectious Anterior UveitisNCT02406209Aldeyra Therapeutics, Inc.45
已完成
2 期
A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior UveitisNCT06679153VivaVision Biotech, Inc89